Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
EMBO Molecular Medicine, 2019 Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains ...
Liping Ye +18 more
doaj +3 more sources
Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
Frontiers in Pharmacology, 2020 Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism
Jingwei Yao +7 more
doaj +3 more sources
Tamoxifen Resistance in Breast Cancer
Biomolecules and Therapeutics, 2012 Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.
Minsun Chang
exaly +4 more sources
Molecular Therapy: Oncolytics, 2020 Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer.
Jun Zhou +9 more
doaj +3 more sources
PARP14-mediated glycolysis enhances Tamoxifen resistance in estrogen receptor + breast cancer cells [PDF]
Discover OncologyBackground Resistance to Tamoxifen is a major challenge in the therapeutic management of estrogen receptor (ER) + breast cancer (BC). Glycolysis, as reported, exerts a crucial influence on the regulation of Tamoxifen resistance in BC, highlighting the ...
Wenju Mo +4 more
doaj +2 more sources
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. [PDF]
PLoS ONEDespite the high sensitivity of estrogen receptor positive (ER+) breast cancer to endocrine therapy, many patients have primary resistance or develop resistance to endocrine therapies.
Xinlei Li +6 more
doaj +2 more sources
Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression [PDF]
Journal of Experimental & Clinical Cancer ResearchBackground Tamoxifen resistance remains a significant challenge in the endocrine therapy of estrogen receptor-positive (ER+) breast cancer. Cancer-associated fibroblasts (CAFs) facilitate therapeutic resistance through exosome secretion, yet the role of ...
Chenghui Wu +14 more
doaj +2 more sources
A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen [PDF]
International Journal of Breast Cancer, 2011 About two thirds of all human breast cancer cases are estrogen receptor positive. The drug of first choice for these patients is tamoxifen.
Renée de Leeuw +2 more
doaj +3 more sources
Non-coding RNA-mediated mechanisms underlying tamoxifen resistance in breast cancer [PDF]
Discover OncologyTamoxifen remains a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer; however, the emergence of drug resistance significantly limits its therapeutic success.
Mohammed Khaleel Jameel +7 more
doaj +2 more sources
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1 [PDF]
Scientific ReportsAlthough tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30–50% of individuals treated with tamoxifen experience relapse.
Hui Yuan +3 more
doaj +2 more sources